ES2286201T3 - Compuestos y procedimientos para la deteccion de carcinomas y sus lesiones precursoras. - Google Patents

Compuestos y procedimientos para la deteccion de carcinomas y sus lesiones precursoras. Download PDF

Info

Publication number
ES2286201T3
ES2286201T3 ES02102814T ES02102814T ES2286201T3 ES 2286201 T3 ES2286201 T3 ES 2286201T3 ES 02102814 T ES02102814 T ES 02102814T ES 02102814 T ES02102814 T ES 02102814T ES 2286201 T3 ES2286201 T3 ES 2286201T3
Authority
ES
Spain
Prior art keywords
dnase
detection
molecules
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02102814T
Other languages
English (en)
Spanish (es)
Inventor
Johannes Coy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2286201T3 publication Critical patent/ES2286201T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
ES02102814T 2002-12-18 2002-12-18 Compuestos y procedimientos para la deteccion de carcinomas y sus lesiones precursoras. Expired - Lifetime ES2286201T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02102814A EP1431762B1 (en) 2002-12-18 2002-12-18 Compounds and methods for detection of carcinomas and their precursor lesions

Publications (1)

Publication Number Publication Date
ES2286201T3 true ES2286201T3 (es) 2007-12-01

Family

ID=32338157

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02102814T Expired - Lifetime ES2286201T3 (es) 2002-12-18 2002-12-18 Compuestos y procedimientos para la deteccion de carcinomas y sus lesiones precursoras.

Country Status (10)

Country Link
US (2) US20060121485A1 (https=)
EP (1) EP1431762B1 (https=)
JP (1) JP4527544B2 (https=)
CN (1) CN1726393B (https=)
AT (1) ATE360817T1 (https=)
AU (1) AU2003302964A1 (https=)
CA (1) CA2510150C (https=)
DE (1) DE60219809T2 (https=)
ES (1) ES2286201T3 (https=)
WO (1) WO2004055514A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60219809T2 (de) * 2002-12-18 2008-01-17 Coy, Johannes F., Dr. Verbindungen und Verfahren zur Nachweiss von Karzinomen und deren Vorstufen
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US9248166B2 (en) * 2003-07-14 2016-02-02 Cls Therapeutics Limited Method for treating oncological diseases
EP2416156B1 (en) 2006-10-18 2015-12-30 Periness Ltd. Method for determining a male fertility status
JP2008253188A (ja) * 2007-04-04 2008-10-23 Tokyo Univ Of Science エンドサイトーシス依存性ｄｎａ取り込み抑制剤、エンドサイトーシス依存性ｄｎａ取り込み促進剤、ウイルス感染阻害剤、ウイルス感染予防剤、及びウイルス感染促進剤、並びに、遺伝子マーカー、モノクローナル抗体、ハイブリドーマ、及びそれらの使用方法。
US7734161B2 (en) * 2007-04-19 2010-06-08 Avago Technologies Ecbu Ip (Singapore) Pte. Ltd. Image stabilization with adaptive shutter control
US9360489B2 (en) 2007-06-11 2016-06-07 Sutter Bay Hospitals Method and kit for dynamic gene expression monitoring
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
CN104267011A (zh) * 2014-09-23 2015-01-07 中国科学院东北地理与农业生态研究所 一种转基因羊卵母细胞的筛选方法
ES2799515T3 (es) 2015-05-22 2020-12-18 Dmitry Dmitrievich Genkin ADN extracelular como una diana terapéutica en la neurodegeneración
CN107677823A (zh) * 2016-08-02 2018-02-09 北京金沐医疗科技有限公司 一种用于检测肿瘤抗原的蛋白芯片试剂盒及其检测方法
CN107677822A (zh) * 2016-08-02 2018-02-09 北京金沐医疗科技有限公司 检测肿瘤标志物的荧光细胞计数检测试剂盒
CN107677820A (zh) * 2016-08-02 2018-02-09 北京金沐医疗科技有限公司 一种检测肿瘤抗原的试剂盒及其检测方法
AU2019209770B2 (en) 2018-01-16 2025-07-31 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
CN109406771B (zh) * 2018-10-26 2023-04-07 安徽大千生物工程有限公司 胱抑素c胶乳增强比浊法检测试剂盒及其制备使用方法
WO2020223265A1 (en) * 2019-04-28 2020-11-05 Essenlix Corporation Rapid pathology/cytology without wash
CN113314220B (zh) * 2021-07-28 2021-11-02 江苏为真生物医药技术股份有限公司 疾病病程监控系统、计算机可读存储介质以及电子设备

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19521046C1 (de) * 1995-06-09 1996-08-08 Deutsches Krebsforsch Protein mit DNase-Aktivität
WO2000052204A2 (en) * 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
EP1249495A1 (de) * 2001-04-11 2002-10-16 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Murine DNase X, diese enthaltendes Arzneimittel und nicht-menschliches Säugetier mit verändertem DNase X-Gen
MXPA04004378A (es) * 2001-11-07 2004-09-10 Univ Arkansas Diagnostico, prognosis e identificacion de objetivos terapeuticos potenciales de mieloma multiple basado en el perfilado de expresion de genes.
CA2499709A1 (en) * 2002-06-19 2003-12-31 Yoichi Furukawa Method for diagnosis of colorectal tumors
DE60219809T2 (de) * 2002-12-18 2008-01-17 Coy, Johannes F., Dr. Verbindungen und Verfahren zur Nachweiss von Karzinomen und deren Vorstufen

Also Published As

Publication number Publication date
JP2006510363A (ja) 2006-03-30
AU2003302964A1 (en) 2004-07-09
WO2004055514A1 (en) 2004-07-01
ATE360817T1 (de) 2007-05-15
EP1431762B1 (en) 2007-04-25
JP4527544B2 (ja) 2010-08-18
DE60219809T2 (de) 2008-01-17
EP1431762A1 (en) 2004-06-23
DE60219809D1 (de) 2007-06-06
US20060121485A1 (en) 2006-06-08
US8759004B2 (en) 2014-06-24
US20080234393A1 (en) 2008-09-25
CA2510150C (en) 2017-11-07
HK1086331A1 (zh) 2006-09-15
CN1726393A (zh) 2006-01-25
CA2510150A1 (en) 2004-07-01
CN1726393B (zh) 2010-04-28

Similar Documents

Publication Publication Date Title
US8759004B2 (en) Compounds and methods for detection of carcinomas and their precursor lesions
ES2201064T3 (es) Transposicion del complejo de ciclina y usos relacionados del mismo.
JP5713036B2 (ja) 癌の検出方法
Garg et al. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer
Yin et al. TSPY is a cancer testis antigen expressed in human hepatocellular carcinoma
Dong et al. Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients
ES2402095T3 (es) Genes y productos de expresión génica que son regulados en forma diferencial en el cáncer de próstata
ES2424976T3 (es) Isoformas relativas al cáncer de componentes de complejos de factores de transcripción como biomarcadores y dianas de fármacos
Wang et al. L552S, an alternatively spliced isoform of XAGE-1, is over-expressed in lung adenocarcinoma
KR101549245B1 (ko) Ｗｎｔ 단백질 및 암의 검출 및 치료
TWI252314B (en) Collapsin response mediator protein-1 (CRMP-1) as an indicator for tumor metastatic diagnosis and treatment
EP1426442A1 (en) Marker molecules associated with colorectal lesions
ES2267291T3 (es) Metodo de diagnostico, control, determinacion del estadio, obtencion de imagenes y tratamiento de los canceres ginecologicos.
US7883896B2 (en) Marker molecules associated with lung tumors
CN1712542B (zh) 肝细胞癌相关的蛋白质分子标记原癌蛋白18的筛选及其应用
Bhardwaj Evaluation of heat shock protein 90α as a biomarker in canine mammary tumor
HK1086331B (en) Compounds and methods for detection of carcinomas and their precursor lesions
Kaur EXPRESSION OF HEAT SHOCK PROTEIN D1 (HSP60) IN CANINE MAMMARY TUMORS
KR20140018411A (ko) Ｗｎｔ 단백질 및 암의 검출 및 치료